Dispatches from CPhI

Gene therapy to drive viral and biologics market, says SAFC

By Gareth Macdonald

- Last updated on GMT

Related tags: Medicine, Biotechnology

SAFC Pharma has added extra viral and biologics capacity at its California plant in a $12m project that allows it to take projects from the lab to commercial scale.

The expansion includes two manufacturing suites that feature disposable bioreactor technologies to support the development and production of viral vaccines and viral therapeutics.

SAFC Pharma business development and marketing director David Backer spoke with in-PharmaTechnologist at CPhI in Madrid, Spain, explaining that the firm expects gene therapy to be the key driver for this type of contract manufacturing offering.

Validation work at the facility is under and SAFC Pharma expects to begin manufacturing operations by the end of the year.

Related topics: Markets & Regulations

Related news

Follow us


View more